166 related articles for article (PubMed ID: 15103632)
1. Is histoaspartic protease a serine protease with a pepsin-like fold?
Andreeva N; Bogdanovich P; Kashparov I; Popov M; Stengach M
Proteins; 2004 May; 55(3):705-10. PubMed ID: 15103632
[TBL] [Abstract][Full Text] [Related]
2. The catalytic significance of the proposed active site residues in Plasmodium falciparum histoaspartic protease.
Parr CL; Tanaka T; Xiao H; Yada RY
FEBS J; 2008 Apr; 275(8):1698-707. PubMed ID: 18312598
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
Pranav Kumar SK; Kulkarni VM
Drug Des Discov; 2001; 17(4):293-313. PubMed ID: 11765133
[TBL] [Abstract][Full Text] [Related]
4. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
[TBL] [Abstract][Full Text] [Related]
6. Evolutionarily conserved functional mechanics across pepsin-like and retroviral aspartic proteases.
Cascella M; Micheletti C; Rothlisberger U; Carloni P
J Am Chem Soc; 2005 Mar; 127(11):3734-42. PubMed ID: 15771507
[TBL] [Abstract][Full Text] [Related]
7. The native conformation of plasmepsin II is kinetically trapped at neutral pH.
Xiao H; Dee D; Yada RY
Arch Biochem Biophys; 2011 Sep; 513(2):102-9. PubMed ID: 21767524
[TBL] [Abstract][Full Text] [Related]
8. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
[TBL] [Abstract][Full Text] [Related]
9. The protonation state of the catalytic aspartates in plasmepsin II.
Friedman R; Caflisch A
FEBS Lett; 2007 Aug; 581(21):4120-4. PubMed ID: 17689534
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the induced-fit mechanism and catalytic activity of the human cytomegalovirus protease homodimer via molecular dynamics simulations.
de Oliveira CA; Guimarães CR; Barreiro G; de Alencastro RB
Proteins; 2003 Sep; 52(4):483-91. PubMed ID: 12910449
[TBL] [Abstract][Full Text] [Related]
11. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
[TBL] [Abstract][Full Text] [Related]
12. Mapping selectivity and specificity of active site of plasmepsins from Plasmodium falciparum using molecular interaction field approach.
Kumar A; Ghosh I
Protein Pept Lett; 2007; 14(6):569-74. PubMed ID: 17627598
[TBL] [Abstract][Full Text] [Related]
13. The prosegment catalyzes native folding of Plasmodium falciparum plasmepsin II.
Jaafar AH; Xiao H; Dee DR; Bryksa BC; Bhaumik P; Yada RY
Biochim Biophys Acta; 2016 Oct; 1864(10):1356-62. PubMed ID: 27378574
[TBL] [Abstract][Full Text] [Related]
14. Crystallographic evidence for noncoplanar catalytic aspartic acids in plasmepsin II resides in the Protein Data Bank.
Robbins AH; Dunn BM; Agbandje-McKenna M; McKenna R
Acta Crystallogr D Biol Crystallogr; 2009 Mar; 65(Pt 3):294-6. PubMed ID: 19237752
[TBL] [Abstract][Full Text] [Related]
15. Parasite killing in Plasmodium vivax malaria by nitric oxide: implication of aspartic protease inhibition.
Sharma A; Eapen A; Subbarao SK
J Biochem; 2004 Sep; 136(3):329-34. PubMed ID: 15598889
[TBL] [Abstract][Full Text] [Related]
16. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
Savarino A; Cauda R; Cassone A
J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
[No Abstract] [Full Text] [Related]
17. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
[TBL] [Abstract][Full Text] [Related]
18. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
19. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
20. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
